The global clinical laboratory services market conducts diagnostic testing worldwide, crucial for identifying biomarkers of chronic diseases and detecting infectious microorganisms. Increasing demand stems from rising cases of infectious diseases, especially in low-income nations. Clinical diagnostic tests, vital for conditions such as cancer and tuberculosis, address a pressing global health concern. In 2020, the World Health Organization reported 10 million global tuberculosis cases, emphasizing the critical role these services play in disease detection and monitoring, particularly in the context of prevalent health challenges.
Access Full Report at https://www.databridgemarketresearch.com/ar/reports/global-clinical-laboratory-services-market
Data Bridge Market Research analyses that the Global Clinical Laboratory Services Market, which was USD 2,76,163.26 million in 2022, is expected to reach USD 4,92,531.06 million by 2030, at a CAGR of 7.50% during the forecast period 2023 to 2030. The rising elderly population is linked to increased disease prevalence, necessitating heightened diagnostic testing. This demographic shift fuels a growing demand for clinical laboratory services as frequent and thorough diagnostics become imperative in addressing the healthcare needs of an aging populace.
Key Findings of the Study
Increasing incidence of infectious diseases is expected to drive the market's growth rate
The escalating incidence of infectious diseases propels the demand for clinical laboratory services, offering vital diagnostic tools for effective patient management. These services encompass a range of tests, including blood count, immunology, allergy testing, and urinalysis. Notably, global statistics from the World Health Organization highlight the substantial burden of diseases such as malaria, sexually transmitted infections, HIV/AIDS, tuberculosis, and cholera, underscoring the critical role of clinical laboratories in addressing and managing these prevalent global health challenges.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2023 to 2030
|
Base Year
|
2022
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Specialty (Clinical Chemistry Testing, Hematology Testing, Microbiology Testing, Immunology Testing, Drugs of Abuse Testing, Cytology Testing, and Genetic Testing), Test Type (Human and Tumor Genetics, Clinical Chemistry), Provider (Independent and Reference Laboratories, Standalone, Hospital-Based Laboratories and Nursing and Physician Office-Based Laboratories), Application (Drug Discovery Related Services, Drug Development Related Services, Bioanalytical, and Lab Chemistry Services, Toxicology Testing Services, Cell, and Gene Therapy Related Services, Preclinical and Clinical Trial Related Services and Other Clinical Laboratory Services), Service Type (Routine Testing Services, Esoteric Services, and Anatomic Pathology Services)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
Market Players Covered
|
Abbott (U.S.), ARUP Laboratories (U.S.), OPKO Health, Inc. (U.S.), Bioscientia Healthcare GmbH (Germany), Charles River Laboratories (U.S.), NeoGenomics Laboratories (U.S.), Genoptix, Inc. (U.S.), Healthscope (Australia), The Laboratory Glassware Co. (U.S.), Laboratory Corporation of America Holdings (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), QIAGEN (Germany), Quest Diagnostics Incorporated (U.S.), Siemens Healthcare Private Limited (Germany), Tulip Diagnostics (P) Ltd. (India), Sonic Healthcare Limited (Australia), Merck KGaA (Germany)
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global clinical laboratory services market is categorized into four notable segments which are based on basis of specialty, provider, application and service type
- On the basis of specialty, the global clinical laboratory services market is segmented into clinical chemistry testing, microbiology testing, hematology testing, immunology testing, cytology testing, genetic testing, and drugs of abuse testing. The clinical chemistry testing segment is expected to dominate the global clinical laboratory services market with a 51.8% market share due to the increase in cases of chronic diseases
The clinical chemistry testing segment of specialty type is anticipated to dominate the clinical laboratory services market
The clinical chemistry testing segment is expected to dominate the global clinical laboratory services market with a 51.8% market share due to the increase in cases of chronic diseases such as liver diseases, cardiovascular diseases, and blood disorders which are surging the demand to use clinical chemistry services
- On the basis of test type, the global clinical laboratory services market is segmented into human and tumor genetics, and clinical chemistry
- On the basis of provider, the global clinical laboratory services market is segmented into independent and reference laboratories, hospital-based laboratories, nursing and physician office-based laboratories. The hospital-based laboratories segment is expected to dominate the global clinical laboratory services market with a 64.4% market share due to the rise in cases of injuries in the hospitals, leading to high patient volumes and high test demand
The hospital-based laboratories segment of provider type is anticipated to dominate the clinical laboratory services market
The hospital-based laboratories segment is expected to dominate the global clinical laboratory services market with a 64.4% market share due to the rise in cases of injuries in the hospitals, leading to high patient volumes and high test demand.
- On the basis of application, the global clinical laboratory services market is segmented into drug discovery related services, drug development related services, bioanalytical and lab chemistry services, toxicology testing services, cell and gene therapy related services, preclinical and clinical trial related services, and other clinical laboratory services. The bioanalytical and lab chemistry services segment is expected to dominate the global clinical laboratory services market with a 46.3% market share as bioanalysis is an important factor in drug discovery and development
- On the basis of service type, the global clinical laboratory services market is segmented into routine testing services, esoteric services, and anatomic pathology services. The routine testing services segment is expected to dominate the global clinical laboratory services market with 75.9% market share because of the increasing cases of chronic diseases such as cardiovascular diseases, liver diseases, and blood disorders, growing the demand to use research and development
Major Players
Data Bridge Market Research recognizes the following companies as the major global clinical laboratory services market players in global clinical laboratory services market are Abbott (U.S.), ARUP Laboratories (U.S.), OPKO Health, Inc. (U.S.), Bioscientia Healthcare GmbH (Germany), Charles River Laboratories (U.S.), NeoGenomics Laboratories (U.S.), Genoptix, Inc. (U.S.), Healthscope (Australia), The Laboratory Glassware Co. (U.S.)
Market Developments
- In July 2021, Laboratory Corporation of America, a prominent player in life sciences, announced the availability of therascreen KRAS PCR Mutation Analysis. This companion diagnostic aids in identifying non-small cell lung cancer (NSCLC) patients eligible for a novel therapy by Amgen. The inclusion of this service expands the company's diagnostic testing portfolio, following FDA approval for various cancers, including breast, lung, colorectal, and bladder cancers. This development underscores the company's commitment to advancing precision medicine and enhancing patient care
- In June 2021, Mayo Clinic and Thermo Fisher Scientific entered a strategic partnership aiming to expedite clinical validation and commercialization of specific next-generation sequencing (NGS), mass spectrometry, and immunology diagnostic tools. This collaboration enhances Mayo Clinic's portfolio by incorporating innovative products and services through advanced diagnostic technologies. The partnership underscores a commitment to delivering cutting-edge solutions to patients, combining Mayo Clinic's clinical expertise with Thermo Fisher Scientific's capabilities in accelerating the development and validation of diagnostic tools
- In 2021, Deep Bio, a prominent player in AI cancer diagnostics, forged a research collaboration agreement with ARUP Laboratories, a leading U.S. reference laboratory. This partnership leverages Deep Bio's AI expertise and ARUP's innovative laboratory research, enhancing capabilities in cancer diagnostics
- In 2021, Abbott achieved regulatory milestones with CE Mark and Health Canada approval for its Amplatzer Steerable Delivery Sheath. This innovative device is tailored for minimally invasive Left Atrial Appendage (LAA) occlusion procedures, complementing Abbott's market-leading Amplatzer Amulet LAA Occluder. The approval signifies a significant advancement in treating atrial fibrillation patients at risk of ischemic stroke, marking the first steerable delivery sheath designed explicitly for this purpose, enhancing precision and effectiveness in cardiac
Regional Analysis
Geographically, the countries covered in the global clinical laboratory services market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
As per Data Bridge Market Research analysis:
North America is the dominant region in the global clinical laboratory services market during the forecast period 2023-2030
North America dominates the clinical laboratory services market, driven by the region's escalating demand for effective treatment and patient care. Factors include a burgeoning elderly population, a high prevalence of chronic diseases, and a well-established healthcare system with a robust reimbursement structure for clinical lab services. These dynamics position North America at the forefront of clinical laboratory services, reflecting the region's commitment to advanced healthcare solutions and addressing the evolving diagnostic needs of its population.
Asia-Pacific is estimated to be the fastest-growing region global clinical laboratory services market in the forecast period 2023-2030
Asia-Pacific (APAC) is expected to dominate the clinical laboratory services market from 2023 to 2030. The region's significant growth is attributed to expanding scientific studies and increasing unmet medical needs. Improved healthcare benefits, heightened public awareness, and enhanced access to high-quality medical care further contribute to the anticipated growth. APAC's dynamic developments in these aspects position it as a key player in shaping the trajectory of the clinical laboratory services market in the coming years.
For more detailed information about the global clinical laboratory services market report, click here – https://www.databridgemarketresearch.com/ar/reports/global-clinical-laboratory-services-market